Tshetiz Dahal
Aim: The aim of this study is to examine the efficacy and safety of immune checkpoint inhibitors (ICIs) as a treatment for advanced nonsmall cell lung cancer (NSCLC). Neo-antigens are significant biomarkers and possible therapeutic targets that are crucial for the diagnosis and care of NSCLC patients. In materials from patients who had surgical therapy for NSCLC, this study sought to assess and define the connections between somatic mutations and possible neoantigens.
Patients and methods: This prospective study examined tissue samples from NSCLC patients who received surgery for their condition. Both tumour tissues and matched normal tissues underwent whole-exome sequencing. Using generative software, candidate neoantigens were predicted, and the associations between different mutational features and the quantity of neoantigens were assessed.
Results: Gene mutations connected to neoantigens occurred less frequently than mutations impacting the entire genome. High neoantigen burden genes exhibited a greater variety and frequency of mutations. There was a positive link between the number of putative neoantigens and missense mutations, code shift insertions/deletions, split-site variations, and mutations involving nonsense. However, only missense mutations show A>G/G>A and C>T/T>C base transitions and A>C/C>A, T>G/G>T, and C>G/G>C base transversions, respectively, had an inverse relationship with the number of neoantigens.d a positive correlation with the quantity of neoantigens in the analysis of multiple linear regression.
Conclusion: The frequency, kind, and base substitution type of mutations were all linked to the quantity of potential neoantigens found in NSCLC cases.
KeywordsNon-small cell lung cancer; Whole exome sequencing; Neoantigens; Tumor neoantigen burden; Genetic mutation characteristics
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu